合成肺表面活性剂CHF5633与猪肺表面活性剂治疗新生儿呼吸窘迫综合征的多中心双盲随机对照试验
该多中心双盲随机对照试验纳入需要呼吸支持且FiO2达到特定阈值(胎龄24+0至26+6周≥0.30,27+0至29+6周≥0.35)的早产儿,随机接受200 mg/kg CHF5633或猪肺表面活性剂poractant alfa治疗。结果显示两组在FiO2、呼吸严重度评分、补救肺表面活性剂使用、支气管肺发育不良发生率及28天死亡率方面均无统计学显著差异,CHF5633疗效与安全性与poractant alfa相似。
要点
- CHF5633与poractant alfa在改善早产儿RDS氧需求方面疗效相似。
- 两组补救肺表面活性剂使用率、BPD发生率及28天死亡率无显著差异。
- CHF5633组药物不良反应发生率3.4%,未检测到免疫原性。
核心结论
- 在患有中重度呼吸窘迫综合征的早产儿中,CHF5633与poractant alfa的疗效和安全性相似。
研究设计与样本
- 多中心、双盲、随机、对照临床试验,共随机123例早产儿,113例接受治疗(CHF5633组56例,poractant alfa组57例)。
- 纳入胎龄24+0至26+6周且FiO2≥0.30、或胎龄27+0至29+6周且FiO2≥0.35以维持血氧饱和度88%-95%的早产儿。
- 随机接受200 mg/kg CHF5633或poractant alfa,必要时以100 mg/kg追加剂量。
主要发现
- 两组FiO2和呼吸严重度评分(FiO2×平均气道压)在基线后各时间点均下降(P < .001),组间无统计学显著差异。
- 补救肺表面活性剂使用在CHF5633组为19例(33.9%),poractant alfa组为17例(29.8%)。
- 支气管肺发育不良在CHF5633组为31例(55.4%),poractant alfa组为32例(56.1%)。
- 28天死亡率在CHF5633组为4例(7.1%),poractant alfa组为3例(5.3%)。
- 药物不良反应在CHF5633组报告2例(3.4%),poractant alfa组报告1例(1.7%);未检测到免疫原性。
临床怎么用
- 对于符合纳入胎龄和FiO2阈值的早产儿RDS,CHF5633可作为poractant alfa的替代选择,疗效与安全性相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare efficacy and safety of a new synthetic surfactant, CHF5633, enriched with surfactant proteins, SP-B and SP-C peptide analogues, with porcine surfactant, poractant alfa, for the treatment of respiratory distress syndrome in infants born preterm. STUDY DESIGN: Neonates born preterm on respiratory support requiring fraction of inspired oxygen (FiO2) ≥0.30 from 240/7 to 266/7 weeks and FiO2 ≥0.35 from 270/7 to 296/7 weeks of gestation to maintain 88%-95% oxygen saturation were randomized to receive 200 mg/kg of CHF5633 or poractant alfa. If necessary, redosing was given at 100 mg/kg. Efficacy end points were oxygen requirement (FiO2, respiratory severity score [FiO2 × mean airway pressure]) in the first 24 hours, 7 and 28 days, discharge home, and/or 36 weeks of postmenstrual age; mortality and bronchopulmonary dysplasia at 28 days and 36 weeks of PMA. Adverse events and immunogenicity were monitored for safety. RESULTS: Of the 123 randomized neonates, 113 were treated (56 and 57 in CHF5633 and poractant alfa groups, respectively). In both arms, FiO2 and respiratory severity score decreased from baseline at all time points (P < .001) with no statistically significant differences between groups. Rescue surfactant use (19 [33.9%] vs 17 [29.8%]), bronchopulmonary dysplasia (31 [55.4%] and 32 [56.1%]), and mortality at day 28 (4 [7.1%] and 3 [5.3%]) were similar in the CHF5633 and poractant alfa groups, respectively. In 2 (3.4%) and 1 (1.7%) neonates, adverse drug reactions were reported in CHF5633 and poractant alfa groups, respectively. No immunogenicity was detected. CONCLUSIONS: Treatment with CHF5633 showed similar efficacy and safety as poractant alfa in neonates born preterm with moderate-to-severe respiratory distress syndrome. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02452476.
引用
- Ramanathan R, Biniwale M, Sekar K, et al. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. J Pediatr. 2020. PMID: 32553868. doi:10.1016/j.jpeds.2020.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。